Detalhe da pesquisa
1.
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
Future Oncol
; 15(32): 3651-3663, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553234
2.
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
J Clin Oncol
; 34(36): 4345-4353, 2016 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27998236
3.
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Eur J Cancer
; 48(15): 2361-8, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22541893
4.
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
J Clin Oncol
; 33(32): 3836-8, 2015 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26282651
5.
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
J Clin Oncol
; 28(19): 3107-14, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20516432